Wechselwirkungen · Cresemba
CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 31–32
HOS-128987 · Präparat HOS-096645
(CYP2B6 induction) Anti-cancer Vinca alkaloids (vincristine, Not studied. No isavuconazole dose vinblastine) Vinca alkaloid concentrations may adjustment necessary. (P-gp substrates) increase. Vinca alkaloids: careful monitoring for any occurrence of (P-gp inhibition) drug toxicity, and dose reduction if required. Cyclophosphamide Not studied. No isavuconazole dose (CYP2B6, CYP3A4 substrate) Active metabolites of adjustment necessary. cyclophosphamide concentrations Cyclophosphamide: careful may increase or decrease. monitoring for any occurrence of lack of efficacy or increased (CYP2B6 induction, CYP3A4 toxicity, and dose adjustment if inhibition) required. Methotrexate Methotrexate: No isavuconazole dose (BCRP, OAT1, OAT3 AUCinf: ↓ 3% adjustment necessary. substrate) Cmax: ↓ 11% 31 Methotrexate: no dose 7-hydroxymetabolite: adjustment required. AUCinf: ↑ 29% Cmax: ↑ 15%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage f297d4e54ac567e12c407f3a10e2d154b27fb2971b0f8c5eb1eafa663ecc87dc · Zeichen 10476–12191 im Abschnitt